Common Stock, par value $0.001 per share
- Symbol
- ALXO
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
ALX Oncology Holdings Inc.
ALXONASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 6, 2026, ALX Oncology Holdings Inc. (the “Company”), issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.…
Press release in this filing
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update →Company context
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn and X.
Current securities
Recent company filings
- SCHEDULE 13D/A - filed by venBio Global Strategic Fund, L.P. regarding ALX ONCOLOGY HOLDINGS INCOct 16, 2026
- Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesOct 15, 2026
- 4 filingAug 18, 2026
- SCHEDULE 13G/A - filed by TCG Crossover GP II, LLC regarding ALX ONCOLOGY HOLDINGS INCAug 14, 2026
- 10-Q filingAug 6, 2026
Registered securities in this filing
ALX ONCOLOGY HOLDINGS INC. · 8-K · Filed 2026-08-06
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, ALX Oncology Holdings Inc. (the “Company”), issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information contained in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly stated by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 alxo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer - - Presented encouraging Phase 1b/2 breast cancer data at ESMO Breast Cancer 2026 that further validate a biomarker-driven development strategy for evorpacept - - Strong enrollment momentum in Phase 1 clinical trial of ALX2004 in EGFR expressing solid tumors with initial safety data on-track for 2H 2026 - - Strengthened leadership team with the appointments of Scott Garland as Chairman of the Board of Directors and Michael Listgarten as General Counsel - SOUTH SAN FRANCISCO, Calif., August 6, 2026 - ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “We continue t…
Open exhibit ↗